Capricor said it plans to use the patents for its clinical program to develop the natriuretic peptide Cenderitide as a treatment for post-acute heart failure. Some of the patents had been co-owned by Medtronic and Capricor.
Financial terms were not disclosed.
“We are extremely pleased to announce the acquisition of these patent rights from Medtronic, as they could extend both the scope and the duration of patent protection for our natriuretic peptide platform,” CEO Linda Marban said in prepared remarks.
“Most importantly, we are now in a position to initiate a clinical program for Cenderitide with an enhanced IP position and we look forward to announcing further milestones as they are achieved,” Marban added.
According to Capricor, there are currently no treatments targeted at reducing the rate of early re-hospitalizations for patients with acute decompensated heart failure.